Additionally, given the promise of the dual GIP/GLP-1 agonist tirzepatide for the treatment of obesity in people with T2D, further trials exploring cardiovascular outcomes with this drug would be welcome to support its use in routine clinical practice. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.